ObsEva SA's oral oxytocin inhibitor nolasiban may be able to increase the chances of a successful pregnancy following IVF treatment, suggest top-line Phase III data. The company claims the product (previously known as OBE001) could be one of the biggest leaps forward in infertility treatment in decades but more studies are needed before it is likely to reach the market.
Initial results from the IMPLANT2 study show an increase in ongoing pregnancy rate at week 10 in patients undergoing in...